NEW YORK (GenomeWeb) – Takeda Pharmaceutical today announced it has signed a partnership with Sanford-Burnham Medical Research Institute to study the role of gene regulatory proteins as targets for the treatment of heart failure.

The partners will screen and develop molecules that may improve the metabolism and function of a damaged heart. Sanford-Burnham and Takeda scientists will collaborate to validate the targets and molecules with a goal of creating new treatments for heart failure.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.